{
    "page": {
        "original_image_path": "/mnt/sh_flex_storage/home/zehanyu/repos/GPT-Paper/pdfs/cancer_review/Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning/pages/page_13.png",
        "current_image_path": "/mnt/sh_flex_storage/home/zehanyu/repos/GPT-Paper/pdfs/cancer_review/Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning/pages_ordered/page_13.png",
        "image_width": 2481,
        "image_height": 3507,
        "regions_num": 2,
        "page_idx": 13
    },
    "regions": [
        {
            "idx": 1,
            "thing": "list",
            "score": 70.24,
            "box": [
                233.9,
                380.0,
                1196.7,
                3082.3
            ],
            "crop_image_path": "/mnt/sh_flex_storage/home/zehanyu/repos/GPT-Paper/pdfs/cancer_review/Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning/crops_ordered/page_13/region_1_list.png",
            "text": "2. Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al.\nLocoregional therapies in the era of molecular and immune treatments for\nhepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2021) 18(5):293-313.\ndoi: 10.1038/s41575-020-00395-0\n\n3. Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune\ncheckpoint inhibitor-based combinations in unresectable hepatocellular\ncarcinoma: current management and future challenges. Expert Rev Gastroenterol\nHepatol (2021) 15(11):1245-51. doi: 10.1080/17474124.2021.1973431\n\n4. De Lorenzo S, Tovoli F, Barbera MA, Garuti F, Palloni A, Frega G, et al.\nMetronomic capecitabine vs. best supportive care in child-pugh b hepatocellular\ncarcinoma: a proof of concept. Sci Rep (2018) 8(1):9997. doi: 10.1038/s41598-018-\n28337-6\n\n5. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al.\nDiagnosis, staging, and management of hepatocellular carcinoma: 2018 practice\nguidance by the american association for the study of liver diseases. Hepatology\n(2018) 68(2):723-50. doi: 10.1002/hep.29913\n\n6. Tsilimigras DI, Bagante F, Sahara K, Moris D, Hyer JM, Wu L, et al. Prognosis\nafter resection of barcelona clinic liver cancer (BCLC) stage 0, a, and b\nhepatocellular carcinoma: A comprehensive assessment of the current BCLC\nclassification. Ann Surg Oncol (2019) 26(11):3693-700. doi: 10.1245/s10434-019-\n07580-9\n\n7. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of\nhepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg\n(2015) 261(5):947-55. doi: 10.1097/SLA.00000000000007 10\n\n8. Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies\nnew therapeutic targets of early-stage hepatocellular carcinoma. Nature (2019) 567\n(7747):257-61. doi: 10.1038/s41586-019-0987-8\n\n9. Qiu J, Peng B, Tang Y, Qian Y, Guo P, Li M, et al. CpG methylation signature\npredicts recurrence in early-stage hepatocellular carcinoma: Results from a\nmulticenter study. J Clin Oncol (2017) 35(7):734-42. doi: 10.1200/\nJCO.2016.68.2153\n\n10. Ji GW, Zhu FP, Xu Q, Wang K, Wu MY, Tang WW, et al. Radiomic features\nat contrast-enhanced CT predict recurrence in early stage hepatocellular\ncarcinoma: A multi-institutional study. Radiology (2020) 294(3):568-79.\ndoi: 10.1148/radiol.2020191470\n\n11. Liu WR, Tian MX, Tang Z, Fang Y, Zhou YF, Song SS, et al. Nine-factor-\nbased immunohistochemistry classifier predicts recurrence for early-stage\nhepatocellular carcinoma after curative resection. Br J Cancer (2020) 123(1):92-\n100. doi: 10.1038/s41416-020-0864-0\n\n12. Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al.\nMicrovascular invasion is a better predictor of tumor recurrence and overall\nsurvival following surgical resection for hepatocellular carcinoma compared to\nthe milan criteria. Ann Surg (2011) 254(1):108-13. doi: 10.1097/\nSLA.0b013e31821ad884\n\n13. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts H. Artificial\nintelligence in radiology. Nat Rev Cancer (2018) 18(8):500-10. doi: 10.1038/\ns41568-018-0016-5\n\n14. Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in\ncancer research and precision medicine. Cancer Discov (2021) 11(4):900-15.\ndoi: 10.1158/2159-8290.CD-21-0090\n\n15. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial\nintelligence in digital pathology - new tools for diagnosis and precision oncology.\nNat Rev Clin Oncol (2019) 16(11):703-15. doi: 10.1038/s41571-019-0252-y\n\n16. Ahn JC, Connell A, Simonetto DA, Hughes C, Shah VH. Application of\nartificial intelligence for the diagnosis and treatment of liver diseases. Hepatology\n(2021) 73(6):2546-63. doi: 10.1002/hep.31603\n\n17. Campanella G, Hanna MG, Geneslaw L, Miraflor A, Werneck Krauss Silva\nV, Busam KJ, et al. Clinical-grade computational pathology using weakly\nsupervised deep learning on whole slide images. Nat Med (2019) 25(8):1301-9.\ndoi: 10.1038/s41591-019-0508-1\n\n18. Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M, Fenyo D,\net al. Classification and mutation prediction from non-small cell lung cancer\nhistopathology images using deep learning. Nat Med (2018) 24(10):1559-67.\ndoi: 10.1038/s41591-018-0177-5\n\n19. Liao H, Long Y, Han R, Wang W, Xu L, Liao M, et al. Deep learning-based\nclassification and mutation prediction from histopathological images of\nhepatocellular carcinoma. Clin Transl Med (2020) 10(2):e102. doi: 10.1002/\nctm2.102\n\n20. Saillard C, Schmauch B, Laifa O, Moarii M, Toldo S, Zaslavskiy M, et al.\nPredicting survival after hepatocellular carcinoma resection using deep learning on\nhistological slides. Hepatology (2020) 72(6):2000-13. doi: 10.1002/hep.31207\n\n21. Shi JY, Wang X, Ding GY, Dong Z, Han J, Guan Z, et al. Exploring\nprognostic indicators in the pathological images of hepatocellular carcinoma based\non deep learning. Gut (2021) 70(5):951-61. doi: 10.1136/gutjnl-2020-320930\n"
        },
        {
            "idx": 2,
            "thing": "list",
            "score": 91.79,
            "box": [
                1287.5,
                380.5,
                2249.0,
                3085.2
            ],
            "crop_image_path": "/mnt/sh_flex_storage/home/zehanyu/repos/GPT-Paper/pdfs/cancer_review/Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning/crops_ordered/page_13/region_2_list.png",
            "text": "22. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC\nstaging classification. Semin Liver Dis (1999) 19(3):329-38. doi: 10.1055/s-2007-\n1007122\n\n23. Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for\nthe management of hepatocellular carcinoma: Updates and insights. Hepatobiliary\nSurg Nutr (2020) 9(4):452-63. doi: 10.21037/hbsn-20-480\n\n24. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance\nof regulatory and cytotoxic t cells is associated with prognosis of hepatocellular\ncarcinoma after resection. J Clin Oncol (2007) 25(18):2586-93. doi: 10.1200/\nJCO.2006.09.4565\n\n25. Otsu N. A threshold selection method from gray-level histograms. IEEE\nTrans syst. man cybern. (1979) 9(1):62-6. doi: 10.1109/TSMC.1979.4310076\n\n26. Reinhard E, Adhikhmin M, Gooch B, Shirley P. Color transfer between\nimages. IEEE Comput Graphics Appl (2001) 21(5):34-41. doi: 10.1109/38.946629\n\n27. Szegedy C, Vanhoucke V, Ioffe S, Shlens J, Wojna Z eds. Rethinking the\ninception architecture for computer vision. In: 2016 IEEE Conference on Computer\nVision and Pattern Recognition (CVPR). 2016; Las Vegas, NV, USA: IEEE\n\n28. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust\nenumeration of cell subsets from tissue expression profiles. Nat Methods (2015) 12\n(5):453-7. doi: 10.1038/nmeth.3337\n\n29. Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net\nreclassification improvement: computation, interpretation, and controversies: a\nliterature review and clinician's guide. Ann Intern Med (2014) 160(2):122-31.\ndoi: 10.7326/M13-1522\n\n30. Zhou B, Khosla A, Lapedriza A, Oliva A, Torralba A editors. Learning Deep\nFeatures for Discriminative Localization. 016 IEEE Conference on Computer Vision\nand Pattern Recognition (CVPR). CVPR (2016) Las Vegas, NV, USA: IEEE.\n\n31. Xi J, Yin J, Liang J, Zhan C, Jiang W, Lin Z, et al. Prognostic impact of\nradiological consolidation tumor ratio in clinical stage IA pulmonary ground glass\nopacities. Front Oncol (2021) 11:616149. doi: 10.3389/fonc.2021.616149\n\n32. Cao Y, Ke R, Wang S, Zhu X, Chen J, Huang C, et al. DNA topoisomerase\nIlalpha and Ki67 are prognostic factors in patients with hepatocellular carcinoma.\nOncol Lett (2017) 13(6):4109-16. doi: 10.3892/o0l.2017.5999\n\n33. Wang C, Zhang Y, Guo K, Wang N, Jin H, Liu Y, et al. Heat shock proteins\nin hepatocellular carcinoma: Molecular mechanism and therapeutic potential. Int J\nCancer (2016) 138(8):1824-34. doi: 10.1002/ijc.29723\n\n34. Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for\nhepatocellular carcinoma diagnosis and treatment. Med Res Rev (2018) 38(2):741-\n67. doi: 10.1002/med.21455\n\n35. Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, et al. Tissue-\ninfiltrating lymphocytes signature predicts survival in patients with early/\nintermediate stage hepatocellular carcinoma. BMC Med (2019) 17(1):106.\ndoi: 10.1186/s12916-019-1341-6\n\n36. Klimov S, Miligy IM, Gertych A, Jiang Y, Toss MS, Rida P, et al. A whole slide\nimage-based machine learning approach to predict ductal carcinoma in situ (DCIS)\nrecurrence risk. Breast Cancer Res (2019) 21(1):83. doi: 10.1186/s13058-019-1165-5\n\n37. Yu KH, Zhang C, Berry GJ, Altman RB, Re C, Rubin DL, et al. Predicting\nnon-small cell lung cancer prognosis by fully automated microscopic pathology\nimage features. Nat Commun (2016) 7:12474. doi: 10.1038/ncomms12474\n\n38. Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, et al.\nIntra-tumoral tertiary lymphoid structures are associated with a low risk of early\nrecurrence of hepatocellular carcinoma. J Hepatol (2019) 70(1):58-65. doi: 10.1016/\nj,jhep.2018.09.003\n\n39. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro\nde Moura M, et al. Identification of an immune-specific class of hepatocellular\ncarcinoma, based on molecular features. Gastroenterology (2017) 153(3):812-26.\ndoi: 10.1053/j.gastro.2017.06.007\n\n40. Lukacs-Kornek V. The role of lymphatic endothelial cells in liver injury and\ntumor development. Front Immunol (2016) 7:548. doi: 10.3389/fimmu.2016.00548\n\n41. Chung JW, Shin E, Kim H, Han HS, Cho JY, Choi YR, et al. Hepatic iron\noverload in the portal tract predicts poor survival in hepatocellular carcinoma after\ncurative resection. Liver Int (2018) 38(5):903-14. doi: 10.1111 /liv.13619\n\n42. Ziol M, Pote N, Amaddeo G, Laurent A, Nault JC, Oberti F, et al.\nMacrotrabecular-massive hepatocellular carcinoma: A distinctive histological\nsubtype with clinical relevance. Hepatology (2018) 68(1):103-12. doi: 10.1002/\nhep.29762\n\n43. Mule S, Galletto Pregliasco A, Tenenhaus A, Kharrat R, Amaddeo G,\nBaranes L, et al. Multiphase liver MRI for identifying the macrotrabecular-\nmassive subtype of hepatocellular carcinoma. Radiology (2020) 295(3):562-71.\ndoi: 10.1148/radiol.2020192230\n\n44. Bauer K, Nitsche U, Slotta~Huspenina J, Drecoll E, von Weyhern CH,\nRosenberg R, et al. High HSP27 and HSP70 expression levels are independent\nadverse prognostic factors in primary resected colon cancer. Cell Oncol (Dordr)\n(2012) 35(3):197-205. doi: 10.1007/s13402-012-0079-3\n"
        }
    ]
}